What is claimed is:

1. An aqueous pharmaceutical formulation comprising:

a VEGF receptor fusion protein~~, anti-VEGF antibody or antigen-binding fragment or VEGF binding molecule~~ at a concentration of at least ~~about~~ 100 mg/ml;

L-arginine;

a sugar;~~about 5% sucrose~~

a histidine-based buffer; and

a~~about 0.03%~~ surfactant;

~~optionally, in association with a further therapeutic agent;~~

wherein the formulation has a pH of ~~about~~ 5.0 to ~~about~~ 6.8.

2. The formulation of claim 1 which is suitable for intravitreal~~intavitreal~~ administration.

3. The formulation of any one of claims 1-2 further comprising sodium sulfate, sodium thiocyanate, glycine, NaCl, sodium aspartate, ~~L-arginine~~ and/or sodium glutamate.

4. The formulation of any one or claims 1-3, wherein the VEGF receptor fusion protein ~~or anti-VEGF antibody or antibody fragment or VEGF binding molecule is~~:

(i) comprises~~a VEGF receptor fusion protein comprising~~ two polypeptides that comprise (1) a VEGFR1 component comprising amino acids 27 to 129 of SEQ ID NO:2; (2) a VEGFR2 component comprising amino acids 130-231 of SEQ ID NO:2; and (3) a multimerization component comprising amino acids 232-457 of SEQ ID NO:2;

~~(ii) a VEGF receptor fusion protein comprising two polypeptides that comprise immunoglobin-like (Ig) domain 2 of a first VEGF receptor and Ig domain 3 of a second VEGF receptor, and a multimerizing component;~~

~~(iii) a VEGF receptor fusion protein comprising two polypeptides that comprise an immunoglobin-like (Ig) domain 2 of a first VEGF receptor, an Ig domain 3 of a second VEGF receptor, an Ig domain 4 of said second VEGF receptor and a multimerizing component;~~

(ii~~iv~~) comprises~~a VEGF receptor fusion protein comprising~~ two polypeptides that comprise an immunoglobin-like (Ig) domain 2 of VEGFR1, an Ig domain 3 of a VEGFR2, and a multimerizing component;

(iii~~iv~~) comprises~~a VEGF receptor fusion protein comprising~~ two polypeptides that comprise an immunoglobin-like (Ig) domain 2 of VEGFR1, an Ig domain 3 of VEGFR2, an Ig domain 4 of VEGFR2 and a multimerizing component; or

(ivvi) comprisesa VEGF receptor fusion protein comprising two VEGFR1R2-FcΔC1(a) polypeptides encoded by the nucleic acid sequence of SEQ ID NO:1; or
(vii) selected from the group consisting of: bevacizumab, ranibizumab, pegaptanib, brolucizumab, an anti-VEGF DARPin and a bispecific anti-VEGF/ANG2 antibody.

5. The formulation of any one or claims 1-4, wherein the VEGF receptor fusion protein or anti-VEGF antibody or antibody fragment or VEGF binding molecule is a VEGF receptor fusion protein is selected from the group consisting of: aflibercept and conbercept.

6. The formulation of any one of claims 1-5 wherein the VEGF receptor fusion protein is afliberceptor anti-VEGF antibody or antibody fragment or VEGF binding molecule is a VEGF receptor fusion protein is a VEGF receptor fusion protein at a concentration of from about 41 to about 275 mg/ml.

7. The formulation of any one of claims 1-6, wherein the VEGF receptor fusion protein is or anti-VEGF antibody or antibody fragment or VEGF binding molecule is a VEGF receptor fusion protein is a VEGF receptor fusion protein at a concentration of:

- about 100 mg/ml;
- about 111.5 mg/ml;
- about 112.0 mg/ml;
- about 113.3 mg/ml;
- about 114.3 mg/ml;
- about 115.6 mg/ml;
- about 116.3 mg/ml;
- about 120 mg/ml;
- about 133 mg/ml;
- about 140 mg/ml;
- about 150 mg/ml;
- about 200 mg/ml;
- about 250 mg/ml; or
- that which contains about 4 mg VEGF receptor fusion protein in about 100 µl or less, about 70 µl or less, about 75 µl or less, about 50 µl or less or about 60 µl or less;
- that which contains about 6 mg VEGF receptor fusion protein in about 100 µl or less, about 70 µl or less, about 75 µl or less, about 50 µl or less or about 60 µl or less;

- that which contains about 8 mg VEGF receptor fusion protein in about 100 µl or less, about 70 µl or less, about 75 µl or less, about 50 µl or less or about 60 µl or less; or
- that which contains about 10 mg VEGF receptor fusion protein in about 100 µl or less, about 70 µl or less, about 75 µl or less, about 50 µl or less or about 60 µl or less.

8. The formulation of any one of claims 1-7 wherein:
(i) the osmolality is about 299 to about 506 mmol/Kg; and/or
(ii) the viscosity is from about 6-15 cP at 20°C.

9. The formulation of any one of claims 1-8 wherein the pH is 5.8 to 6.5.

10. The formulation of claim 9 wherein the pH is about 5.8.

11. The formulation of any one of claims 1-10, wherein the surfactant is a non-ionic surfactant.

12. The formulation of claim 11, wherein the non-ionic surfactant is selected from the group consisting of polysorbate 20, polysorbate 80, poloxamer 188, polyethylene glycol 3350 and mixtures thereof.

13. The formulation of any one of claims 1-12, wherein the histidine-based buffer comprises is histidine hydrochloride.

14. The formulation of claim 13 comprising about 10 mM to 20 mM histidine-based buffer hydrochloride.

15. The formulation of any one of claims 1-14, wherein the sugar is sucrosecomprising a thermal stabilizer which is a sugar.

16. The formulation of any one of claims 1-14claim 15, wherein the sugar is sucrose, mannitol, sorbitol or trehalose.

17. The formulation of any one of claims 15-16 comprising about 2.5% (w/v), about 5% (w/v), about 8% (w/v), about 10% (w/v) or about 20% (w/v) sugar, which is sucrose, mannitol, sorbitol or trehalose.

18. The formulation of any one of claims 1-17 comprising surfactant at a concentration of about 0.03% (w/v).

19. The formulation of any one of claims 1-18, wherein the L-arginine is~~comprising~~ L-arginine monohydrochloride.

20. The formulation of any one of claims 1-19 wherein the VEGF receptor fusion protein~~ or anti-VEGF antibody or antibody fragment or VEGF binding molecule is a VEGF receptor fusion protein which~~ has less than ~~about~~ 3.5% high molecular weight species immediately after manufacture and purification and/or less than or equal to ~~about~~ 6% high molecular weight species after storage for ~~about~~ 24 months at ~~about~~ 2-8ºC.

21. A formulation comprising the components in a formulation selected from the group consisting of:

~~Formulation A: 80 mg/ml aflibercept, 10 mM histidine-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 20, and 40 mM sodium chloride, with a pH of 5.8 to 6.2;~~

~~Formulation B: 80 mg/ml aflibercept, 10 mM phosphate-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 20, and 40 mM sodium chloride, with a pH of 5.8 to 6.2;~~

~~Formulation C: 80 mg/ml aflibercept, 10 mM citrate-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 20, and 40 mM sodium chloride, with a pH of 5.8 to 6.2;~~

~~Formulation D: 80 mg/ml aflibercept, 10 mM histidine-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 80, and 40 mM sodium chloride, with a pH of 6.2;~~

~~Formulation E: 80 mg/ml aflibercept, 10 mM phosphate-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 80, and 40 mM sodium chloride, with a pH of 5.8 to 6.2;~~

~~Formulation F: 80 mg/ml aflibercept, 10 mM citrate-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 80, and 40 mM sodium chloride, with a pH of 5.8 to 6.2.~~

~~Formulation G: 80 mg/ml aflibercept, 10 mM histidine-based buffer, 8% (w/v) sucrose, and 0.03% (w/v) polysorbate 20, with a pH of 5.8 to 6.2;~~

~~Formulation H: 80 mg/ml aflibercept, 10 mM phosphate-based buffer, 8% (w/v) sucrose, and 0.03% (w/v) polysorbate 20, with a pH of 5.8 to 6.2;~~

~~Formulation I: 80 mg/ml aflibercept, 10 mM citrate-based buffer, 8% (w/v) sucrose, and 0.03% (w/v) polysorbate 20, with a pH of 5.8 to 6.2;~~

~~Formulation J: 80 mg/ml aflibercept, 10 mM histidine-based buffer, 8% (w/v) sucrose, and 0.03% (w/v) polysorbate 80, with a pH of 5.8 to 6.2;~~

~~Formulation K: 80 mg/ml aflibercept, 10 mM phosphate-based buffer, 8% (w/v) sucrose, and 0.03% (w/v) polysorbate 80, with a pH of 5.8 to 6.2;~~

~~Formulation L: 80 mg/ml aflibercept, 10 mM citrate-based buffer, 8% (w/v) sucrose, and 0.03% (w/v) polysorbate 80, with a pH of 5.8 to 6.2;~~

~~Formulation M: 150 mg/ml aflibercept, 10 mM histidine-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 20, and 40 mM sodium chloride, with a pH of 5.8 to 6.2;~~

~~Formulation N: 150 mg/ml aflibercept, 10 mM phosphate-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 20, and 40 mM sodium chloride, with a pH of 5.8 to 6.2;~~

~~Formulation O: 150 mg/ml aflibercept, 10 mM citrate-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 20, and 40 mM sodium chloride, with a pH of 5.8 to 6.2;~~

~~Formulation P: 150 mg/ml aflibercept, 10 mM histidine-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 80, and 40 mM sodium chloride, with a pH of 6.2;~~

~~Formulation Q: 150 mg/ml aflibercept, 10 mM phosphate-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 80, and 40 mM sodium chloride, with a pH of 5.8 to 6.2;~~

~~Formulation R: 150 mg/ml aflibercept, 10 mM citrate-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 80, and 40 mM sodium chloride, with a pH of 5.8 to 6.2;~~

~~Formulation S: 150 mg/ml aflibercept, 10 mM histidine-based buffer, 8% (w/v) sucrose, and 0.03% (w/v) polysorbate 20, with a pH of 5.8 to 6.2;~~

~~Formulation T: 150 mg/ml aflibercept, 10 mM phosphate-based buffer, 8% (w/v) sucrose, and 0.03% (w/v) polysorbate 20, with a pH of 5.8 to 6.2;~~

~~Formulation U: 150 mg/ml aflibercept, 10 mM citrate-based buffer, 8% (w/v) sucrose, and 0.03% (w/v) polysorbate 20, with a pH of 5.8 to 6.2;~~

~~Formulation V: 150 mg/ml aflibercept, 10 mM histidine-based buffer, 8% (w/v) sucrose, and 0.03% (w/v) polysorbate 80, with a pH of 5.8 to 6.2;~~

~~Formulation W: 150 mg/ml aflibercept, 10 mM phosphate-based buffer, 8% (w/v) sucrose, and 0.03% (w/v) polysorbate 80, with a pH of 5.8 to 6.2;~~

~~Formulation X: 150 mg/ml aflibercept, 10 mM citrate-based buffer, 8% (w/v) sucrose, and 0.03% (w/v) polysorbate 80, with a pH of 5.8 to 6.2;~~

~~Formulation Y: 80 mg/ml conbercept, 10 mM histidine-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 20, and 40 mM sodium chloride, with a pH of 5.8 to 6.2;~~

~~Formulation Z: 80 mg/ml conbercept, 10 mM phosphate-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 20, and 40 mM sodium chloride, with a pH of 5.8 to 6.2;~~

~~Formulation AA: 80 mg/ml conbercept, 10 mM citrate-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 20, and 40 mM sodium chloride, with a pH of 5.8 to 6.2;~~

~~Formulation BB: 80 mg/ml conbercept, 10 mM histidine-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 80, and 40 mM sodium chloride, with a pH of 6.2;~~

~~Formulation CC: 80 mg/ml conbercept, 10 mM phosphate-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 80, and 40 mM sodium chloride, with a pH of 5.8 to 6.2;~~

~~Formulation DD: 80 mg/ml conbercept, 10 mM citrate-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 80, and 40 mM sodium chloride, with a pH of 5.8 to 6.2;~~

~~Formulation EE: 80 mg/ml conbercept, 10 mM histidine-based buffer, 8% (w/v) sucrose, and 0.03% (w/v) polysorbate 20, with a pH of 5.8 to 6.2;~~

~~Formulation FF: 80 mg/ml conbercept, 10 mM phosphate-based buffer, 8% (w/v) sucrose, and 0.03% (w/v) polysorbate 20, with a pH of 5.8 to 6.2;~~

~~Formulation GG: 80 mg/ml conbercept, 10 mM citrate-based buffer, 8% (w/v) sucrose, and 0.03% (w/v) polysorbate 20, with a pH of 5.8 to 6.2;~~

~~Formulation HH: 80 mg/ml conbercept, 10 mM histidine-based buffer, 8% (w/v) sucrose, and 0.03% (w/v) polysorbate 80, with a pH of 5.8 to 6.2;~~

~~Formulation II: 80 mg/ml conbercept, 10 mM phosphate-based buffer, 8% (w/v) sucrose, and 0.03% (w/v) polysorbate 80, with a pH of 5.8 to 6.2;~~

~~Formulation JJ: 80 mg/ml conbercept, 10 mM citrate-based buffer, 8% (w/v) sucrose, and 0.03% (w/v) polysorbate 80, with a pH of 5.8 to 6.2;~~

~~Formulation KK: 150 mg/ml conbercept, 10 mM histidine-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 20, and 40 mM sodium chloride, with a pH of 5.8 to 6.2;~~

~~Formulation LL: 150 mg/ml conbercept, 10 mM phosphate-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 20, and 40 mM sodium chloride, with a pH of 5.8 to 6.2;~~

~~Formulation MM: 150 mg/ml conbercept, 10 mM citrate-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 20, and 40 mM sodium chloride, with a pH of 5.8 to 6.2;~~

~~Formulation NN: 150 mg/ml conbercept, 10 mM histidine-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 80, and 40 mM sodium chloride, with a pH of 6.2;~~

~~Formulation OO: 150 mg/ml conbercept, 10 mM phosphate-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 80, and 40 mM sodium chloride, with a pH of 5.8 to 6.2;~~

~~Formulation PP: 150 mg/ml conbercept, 10 mM citrate-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 80, and 40 mM sodium chloride, with a pH of 5.8 to 6.2;~~

~~Formulation QQ: 150 mg/ml conbercept, 10 mM histidine-based buffer, 8% (w/v) sucrose, and 0.03% (w/v) polysorbate 20, with a pH of 5.8 to 6.2;~~

~~Formulation RR: 150 mg/ml conbercept, 10 mM phosphate-based buffer, 8% (w/v) sucrose, and 0.03% (w/v) polysorbate 20, with a pH of 5.8 to 6.2;~~

~~Formulation SS: 150 mg/ml conbercept, 10 mM citrate-based buffer, 8% (w/v) sucrose, and 0.03% (w/v) polysorbate 20, with a pH of 5.8 to 6.2;~~

~~Formulation TT: 150 mg/ml conbercept, 10 mM histidine-based buffer, 8% (w/v) sucrose, and 0.03% (w/v) polysorbate 80, with a pH of 5.8 to 6.2;~~

~~Formulation UU: 150 mg/ml conbercept, 10 mM phosphate-based buffer, 8% (w/v) sucrose, and 0.03% (w/v) polysorbate 80, with a pH of 5.8 to 6.2;~~

~~Formulation VV: 150 mg/ml conbercept, 10 mM citrate-based buffer, 8% (w/v) sucrose, and 0.03% (w/v) polysorbate 80, with a pH of 5.8 to 6.2;~~

~~Formulation WW: 140 mg/ml VEGF receptor fusion protein, 10 mM histidine-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 20, and 50 mM taurine, with a pH of 5.8;~~

Formulation XX: 140 mg/ml VEGF receptor fusion protein, 20 mM histidine-based buffer, 4% (w/v) proline, 0.03% (w/v) polysorbate 20, and 50 mM arginine hydrochloride, with a pH of 5.8;

~~Formulation YY: 140 mg/ml VEGF receptor fusion protein, 20 mM histidine-based buffer, 2.5% (w/v) sucrose, 2.0 % (w/v) proline, 0.03% (w/v) polysorbate 20, and 50 mM taurine, with a pH of 5.8;~~

Formulation ZZ: 140 mg/ml VEGF receptor fusion protein, 10 mM histidine-based buffer, 2.5% (w/v) sucrose, 2.0% (w/v) proline, 0.03% (w/v) polysorbate 20, and 50 mM arginine hydrochloride, with a pH of 5.8;

~~Formulation AAA: 140 mg/ml VEGF receptor fusion protein, 20 mM histidine-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 20, and 50 mM PSA, with a pH of 5.8;~~

~~Formulation BBB: 140 mg/ml VEGF receptor fusion protein, 20 mM histidine-based buffer, 2.5% (w/v) sucrose, 2.0% (w/v) proline, 0.03% (w/v) polysorbate 20, and 50 mM PSA, with a pH of 5.8;~~

Formulation CCC: 80, 100, 120 or 140 mg/ml VEGF receptor fusion protein, 20 mM histidine-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 20, and 50 mM arginine hydrochloride, with a pH of 5.8;

~~Formulation DDD: 140 mg/ml VEGF receptor fusion protein, 10 mM histidine-based buffer, 4% (w/v) proline, 0.03% (w/v) polysorbate 20, and 50 mM PSA, with a pH of 5.8;~~

~~Formulation EEE: 140 mg/ml VEGF receptor fusion protein, 20 mM histidine-based buffer, 5% (w/v) sucrose, and 0.03% (w/v) polysorbate 20 and no thermal stabilizer, with a pH of 5.8;~~

~~Formulation FFF: 140 mg/ml VEGF receptor fusion protein, 10 mM sodium phosphate, 5 % (w/v) sucrose and 0.03 % polysorbate 20 with a pH of 6.2;~~

~~Formulation GGG: 140 mg/ml VEGF receptor fusion protein; 20 mM histidine, pH 5.8; 5% Sucrose; 0.03% polysorbate 20; 50 mM sodium sulfate;~~

~~Formulation HHH: 140 mg/ml VEGF receptor fusion protein; 20 mM histidine, pH 5.8; 5% sucrose; 0.03% polysorbate 20; 50 mM sodium thiocyanate;~~

~~Formulation III: 140 mg/ml VEGF receptor fusion protein; 20 mM histidine, pH 5.8; 5% sucrose, 0.03% polysorbate 20; 40 mM sodium citrate;~~

~~Formulation JJJ: 140 mg/ml VEGF receptor fusion protein; 20 mM histidine, pH 5.8; 5% Sucrose, 0.03% polysorbate 20; 50 mM glycine;~~

~~Formulation KKK: 140 mg/ml VEGF receptor fusion protein; 20 mM histidine, pH 5.8; 5% sucrose, 0.03% polysorbate 20; 50 mM sodium chloride;~~

~~Formulation LLL: 140 mg/ml VEGF receptor fusion protein; 20 mM Histidine, pH 5.8; 5% sucrose; 0.03% polysorbate 20; 50 mM lysine;~~

~~Formulation MMM: 140 mg/ml VEGF receptor fusion protein; 20 mM histidine, pH 5.8; 5% sucrose; 0.03% polysorbate 20; 50 mM sodium aspartate;~~

~~Formulation NNN: 140 mg/ml VEGF receptor fusion protein; 20 mM histidine, pH 5.8; 5% sucrose; 0.03% polysorbate 20; 50 mM sodium glutamate;~~

Formulation OOO: 140 mg/ml VEGF receptor fusion protein; 20 mM histidine, pH 5.8; 5% sucrose; 0.03% polysorbate 20; 50 mM sodium Citrate; 50 mM arginine hydrochloride;

Formulation PPP: 140 mg/ml VEGF receptor fusion protein; 20 mM histidine, pH 5.8; 5% sucrose; 0.03% polysorbate 20; 50mM glycine; 50 mM arginine hydrochloride;

Formulation QQQ: 140 mg/ml VEGF receptor fusion protein; 20 mM histidine, pH 5.8; 5% sucrose; 0.03% polysorbate 20; 50 mM sodium aspartate; 50 mM arginine hydrochloride;

Formulation RRR: 140 mg/ml VEGF receptor fusion protein; 20 mM histidine, pH 5.8; 5% sucrose; 0.03% polysorbate 20; 50 mM sodium glutamate; 50 mM arginine hydrochloride;

Formulation SSS: 140 mg/ml VEGF receptor fusion protein; 20 mM His, pH 5.8; 5% sucrose; 0.03% polysorbate 20; 10 mM L-arginine hydrochloride;

Formulation TTT: 140 mg/ml VEGF receptor fusion protein; 20 mM His, pH 5.8; 5% sucrose; 0.03% polysorbate 20; 100 mM L-arginine hydrochloride;

~~Formulation UUU: 30 mg/ml VEGF receptor fusion protein, 10% sucrose, 10 mM phosphate, 0.03% polysorbate 20, pH 6.2;~~

~~Formulation VVV: 30 mg/ml VEGF receptor fusion protein, 20% sucrose, 10 mM phosphate, 0.03% polysorbate 20, pH 6.2;~~

~~Formulation WWW: 60 mg/ml VEGF receptor fusion protein, 10% sucrose, 10 mM phosphate, 0.03% polysorbate 20, pH 6.2;~~

~~Formulation XXX: 60 mg/ml VEGF receptor fusion protein, 20% sucrose, 10 mM phosphate, 0.03% polysorbate 20, pH 6.2;~~

~~Formulation YYY: 120 mg/ml VEGF receptor fusion protein, 10% sucrose, 10 mM phosphate, 0.03% polysorbate 20, pH 6.2;~~

~~Formulation ZZZ: 120 mg/ml VEGF receptor fusion protein, 20% sucrose, 10 mM phosphate, 0.03% polysorbate 20, pH 6.2;~~

~~Formulation AAAA: 120 mg/ml VEGF receptor fusion protein, 10% sucrose, 10 mM phosphate, 0.03% polysorbate 20, 50 mM NaCl, pH 6.2;~~

~~Formulation BBBB: 120 mg/ml VEGF receptor fusion protein, 20% sucrose, 10 mM phosphate, 0.03% polysorbate 20, 50 mM NaCl, pH 6.2;~~

~~Formulation CCCC: 140 mg/ml VEGF receptor fusion protein, 10 mM sodium phosphate, 5% sucrose, 40 mM sodium chloride, 0.03% PS20, pH 6.2;~~

Formulation DDDD: 80.0 mg/ml VEGF receptor fusion protein, 20 mM histidine-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 20, and 50 mM L-arginine monohydrochloride, with a pH of 5.8;

Formulation EEEE: 120.0 mg/ml VEGF receptor fusion protein, 20 mM histidine-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 20, and 50 mM L-arginine monohydrochloride, with a pH of 5.8;

Formulation FFFF: 113.3 mg/ml VEGF receptor fusion protein, 20 mM histidine-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 20, and 50 mM L-arginine monohydrochloride, with a pH of 5.8;

Formulation GGGG: 114.3 mg/ml VEGF receptor fusion protein, 10 mM histidine-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 20, and 50 mM L-arginine monohydrochloride, with a pH of 5.8;

Formulation HHHH: 100.0 mg/ml VEGF receptor fusion protein, 20 mM histidine-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 20, and 50 mM L-arginine monohydrochloride, with a pH of 5.8; ~~and~~

Formulation IIII: 133.3 mg/ml VEGF receptor fusion protein, 20 mM histidine-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 20, and 50 mM L-arginine monohydrochloride, with a pH of 5.8;

Formulation JJJJ: 150 mg/ml aflibercept, 10 mM sodium phosphate, 8% (w/v) sucrose, 0.03% (w/v) polysorbate 20 and 50 mM arginine hydrochloride, pH 6.2; and

Formulation KKKK: 114.3 mg/ml VEGF receptor fusion protein, 20 mM histidine-based buffer, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 20, and 50 mM L-arginine monohydrochloride, with a pH of 5.8~~;~~

~~Formulation LLLL: 90 mg/ml VEGF receptor fusion protein, 10 mM histidine, 5% (w/v) sucrose, 0.03% (w/v) polysorbate 20, pH 5.75; and~~

~~Formulation MMMM: 90 mg/ml VEGF receptor fusion protein, 10 mM histidine, 7% (w/v) sucrose, 0.03% (w/v) polysorbate 20, pH 5.75~~.

22. The formulation of claim 21, wherein the VEGF receptor fusion protein is aflibercept or conbercept.

23. The formulation of any one of claims 21-22 wherein the VEGF receptor fusion protein has less than ~~about~~ 3.5% high molecular weight species immediately after manufacture and purification and/or less than or equal to ~~about~~ 6% high molecular weight species after storage for ~~about~~ 24 months at ~~about~~ 2-8ºC.

24. A container or injection device comprising the formulation of any one of claims 1-23.

25. The container or injection device of claim 24, which is a vial, syringe, autoinjector or pre-filled syringe.

26. A method for preparing the formulation of any one of claims 1-23, comprising combining the components of said formulation into a single composition.

27. The method of claim 26, further comprising loading a volume of the formulation into a syringe.

28. A formulation which is the product of the method of any one of claims 26-27.

29. Use of~~A method for administering~~ a formulation of any one of claims 1-22 and 27 in the manufacture of a medicament for the treatment of an angiogenic eye disorder in a subject, wherein the medicament is to be administered via intraocular injection~~ to a subject comprising intraocularly injecting the formulation~~ into an~~the~~ eye of the subject.

~~30. A method for treating an angiogenic eye disorder in a subject in need thereof comprising administering an intraocular injection of more than about 2 mg of a VEGF receptor fusion protein to the eye of the subject.~~

~~31. The method of claim 30 comprising administering about 4 mg, about 6 mg, about 8 mg or about 10 mg of the VEGF receptor fusion protein to the eye of the subject.~~

30~~32~~. Use of a VEGF receptor fusion protein in a formulation of any one of claims 1-23 or 28 in the manufacture of a medicament~~A method~~ for the treatment of ~~treating~~ an angiogenic eye disorder in a subject, wherein the medicament is to be administered via intraocular injection into an eye of the subject at a dosage of~~in need thereof, the method comprising intraocularly~~

injecting more than about 2 8 mg or more of the VEGF receptor fusion protein in a formulation of any one of claims 1-23 and 28 into an eye of the subject.

3133. The usemethod of claim 3032, wherein the medicament is to be administered into the eye of the subject at a dosage of comprising injecting about 4 mg, about 6 mg, about 8 mg or about 10 mg of the VEGF receptor fusion protein into the eye of the subject.

3234. The usemethod of any one of claims 30-3133, wherein the formulation is to be administered viaintraocular injection is an intravitreal injection.

3335. The usemethod of any one of claims 30-3234, wherein the angiogenic eye disorder is age-related macular degeneration (wet), macular edema, macular edema following retinal vein occlusion, retinal vein occlusion (RVO), central retinal vein occlusion (CRVO) branch retinal vein occlusion (BRVO), diabetic macular edema (DME), choroidal neovascularization (CNV), iris neovascularization, neovascular glaucoma, post-surgical fibrosis in glaucoma, proliferative vitreoretinopathy (PVR), optic disc neovascularization, corneal neovascularization, retinal neovascularization, vitreal neovascularization, pannus, pterygium, vascular retinopathy, diabetic retinopathy, non-proliferative diabetic retinopathy and/or proliferative diabetic retinopathy.

3436. The usemethod of any one of claims 32-3330-35 wherein the intravitreal injection of the VEGF receptor fusion protein is to be administered at a dosage of administered in about 100 microliters or less, about 90 microliters, about 80 microliters, about 75 microliters or less, about 70 microliters, about 60 microliters or about 50 microliters.

3537. The usemethod of any one of claims 30-3436, wherein the VEGF receptor fusion protein is contained within a formulation comprising: about 5% sucrose; a histidine buffer; and about 0.03% surfactant.

3638. The usemethod of any one or claims 32-3530-37 wherein the medicament is to be administered via intravitreal injectionmore than about 2.0 mg of the VEGF receptor fusion protein is injected once every 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24 weeks.